Prognostic factors in malignant pleural mesothelioma: A retrospective study of 60 Turkish patients

Koyuncu, Adem; Köksal, Deniz; Özmen, Özlem; Demırağ, Funda; Bayız, Hülya; Aydoğdu, Koray; Berkoğlu, Mine

doi:10.4103/0973-1482.138094

Cited by 8 publications

(11 citation statements)

References 33 publications

(50 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Analyzing the full-text version of the remaining 31 studies, there were 12 excluded (4 articles including patients with MPM recurrence); 3 articles from the same referring center; 3 articles including MPM patients with both baseline (pre-treatment) and post-treatment PET, but not reporting prognostic analysis of baseline PET data; 1study with a prognostic analysis performed only in a subgroup population; and 1 article including patients with both peritoneal and pleural mesothelioma, with no separate information on MPM subgroup). Finally, 19 studies were included and analyzed in this review [ 29 , 32 , 33 , 34 , 35 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ].…”

Section: Resultsmentioning

confidence: 99%

“…In this context, selected patients with a homogeneous clinical staging were exclusively analyzed only in three papers [ 29 , 45 , 50 ]. Regarding clinical indications of PET exams, in all the included studies, 18 F-FDG PET imaging was performed for staging purpose (i.e., in MPM patients at first diagnosis) according to the research topic and inclusion criteria of our review: in 17/19 studies, 18 F-FDG PET imaging was exclusively performed at baseline (before any therapy) [ 32 , 33 , 34 , 35 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 47 , 48 , 49 , 50 ]; in the remaining 2/19 studies [ 29 , 46 ], a second PET scan after systemic therapy was performed for treatment response assessment. Information on talc pleurodesis performed before PET scans was available in 13/19 studies; almost half of these studies (6/13) included a cohort of patients submitted to previous talc pleurodesis, ranging from 30% to 50% [ 29 , 32 , 34 , 41 , 44 , 46 ].…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

Taralli

Giancipoli

Caldarella

et al. 2021

JCM

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an aggressive malignancy, frequently diagnosed at locally-advanced/metastatic stages. Due to a very poor prognosis and limited treatment options, the need to identify new prognostic markers represents a great clinical challenge. The prognostic role of metabolic information derived from Positron Emission Tomography (PET) with 18F-Fluoro-deoxy-glucose (18F-FDG) has been investigated in different MPM settings, however with no definitive consensus. In this comprehensive review, the prognostic value of FDG-PET imaging exclusively performed at staging in MPM patients was evaluated, conducting a literature search on PubMed/MEDLINE from 2010 to 2020. From the 19 selected studies, despite heterogeneity in several aspects, staging FDG-PET imaging emerges as a valuable prognostic biomarker, with higher tumor uptake predictive of worse prognosis, and with volumetric metabolic parameters like Metabolic Tumor Volume, (MTV) and Total Lesion Glycolisis (TLG) performing better than SUVmax. However, PET uptake parameters were not always confirmed as independent prognostic factors, especially in patients previously treated with pleurodesis and with a non-epithelioid histotype. Future prospective studies in larger and clinically homogeneous populations, and using more standardized methods of PET images analysis, are needed to further validate the value of staging FDG-PET in the prognostic MPM stratification, with a potential impact on better patient-tailored treatment planning, in the perspective of personalized medicine.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

Taralli

Giancipoli

Caldarella

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…It represents a critical problem for clinicians in its diagnosis and treatment. MPM is usually presented in late stages with a median survival of less than one year [ 3 ]. Early diagnosis and adequate treatment prove to remain the predominant factors in the treatment of early MPM.…”

Section: Introductionmentioning

confidence: 99%

Assessment of Glutathione Peroxidase-1 (GPX1) Gene Expression as a Specific Diagnostic and Prognostic Biomarker in Malignant Pleural Mesothelioma

et al. 2021

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a malignant tumor of the mesothelial lining of the thorax. It has been related to frequent exposure to asbestos. Diagnosis of malignant pleural mesothelioma is considered a criticizing problem for clinicians. Early diagnosis and sufficient surgical excision of MPM are considered the cornerstone success factors for the management of early MPM. Glutathione peroxidase-1 (GPX1) is an intracellular protein found to be extensively distributed in all cells, and it belongs to the GPX group. In the current study, we included ninety-eight patients with MPM that underwent surgery at the Zagazig University Hospital in Egypt. We assessed GPX1 gene expression level as it was thought to be related to pathogenicity of cancer in a variety of malignant tumors. We observed a significant elevation in GPX1-mRNA levels in MPM relative to the nearby normal pleural tissues. It was found to be of important diagnostic specificity in the differentiation of MPM from normal tissues. Moreover, we studied the survival of patients in correlation to the GPX1 expression levels and we reported that median overall survival was about 16 months in patients with high GPX1 expression levels, while it was found to be about 40 months in low GPX1 levels.

show abstract

“…MiRNAs play an important role in the regulation of various functions of cells 7 , 8 . Many miRNAs are upregulated or downregulated in human tumors, and abnormal expression of miRNAs could promote or suppress the development of tumors by affecting the expression levels of target proteins 9 , 10 . If miRNAs act on target proteins that affect absorption, metabolism, and distribution of drugs, or affect a target receptor that has an effect on clinical efficacy, these miRNAs could significantly affect the efficacy of anti-tumor drugs.…”

Section: Introductionmentioning

confidence: 99%

Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy

Tian

Sun

Zhang

et al. 2018

Cancer Biology & Medicine

View full text Add to dashboard Cite

Objective:Research has demonstrated that microRNA (miR)-106a is related to cisplatin resistance. We investigated the expression of miR-106a in the serum of patients with non-small cell lung cancer (NSCLC) and their sensitivity to chemotherapy by cisplatin combined with gemcitabine.Methods:Eighty-five NSCLC patients, who completed four cycles of gemcitabine and cisplatin chemotherapy, volunteered for this study and their serum samples were collected. Serum samples from 60 healthy subjects were used as controls. Real-time quantitative polymerase chain reaction (real-time qPCR) was used to quantify the level of miR-106a in the serum. Demographic and survival data of these patients were collected for the analysis.Results:The expression of miR-106a in the serum of NSCLC patients was significantly higher than that of healthy subjects (P < 0.001). The expression of miR-106a was not correlated with patients' gender, age, tumor size, lymphatic metastasis, and pathological types; but was correlated with patients' tumor staging ( P = 0.003). After chemotherapy, serum miR-106a expression decreased in patients. The decrease in miR-106a expression in the chemotherapy-sensitive group was much higher than that in the chemotherapy-resistant group. Survival analysis shows that NSCLC patients with high expression of miR-106a have a poorer prognosis. The overall survival of NSCLC patients in the chemotherapy-sensitive group was significantly higher than that in the chemotherapy-resistant group. Conclusions:High expression of miR-106a may be involved in the development of NSCLC. MiR-106a has significance in the prognosis of NSCLC. The level of miR-106a in the serum can be a useful parameter in screening for drug resistance during cisplatin-based chemotherapy.

show abstract

Prognostic factors in malignant pleural mesothelioma: A retrospective study of 60 Turkish patients

Abstract: Presence of leukocytosis, advanced disease stages, supportive therapy alone, and higher MAI were found to be negative prognostic factors in patients with MPM.

Cited by 8 publications

References 33 publications

The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

The Prognostic Value of 18F-FDG PET Imaging at Staging in Patients with Malignant Pleural Mesothelioma: A Literature Review

Assessment of Glutathione Peroxidase-1 (GPX1) Gene Expression as a Specific Diagnostic and Prognostic Biomarker in Malignant Pleural Mesothelioma

Clinical significance of miRNA - 106a in non-small cell lung cancer patients who received cisplatin combined with gemcitabine chemotherapy

Contact Info

Product

Resources

About